Hit Generation in TB Drug Discovery: From Genome to Granuloma

• Published in: Chemical reviews Vol. 118; no. 4; pp. 1887 - 1916
• Main Authors: Yuan, Tianao, Sampson, Nicole S
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 28.02.2018
• Subjects: Antitubercular Agents - pharmacology; Antitubercular Agents - therapeutic use; Complexity; Drug delivery systems; Drug Discovery; Epidemics; Focus screens; Genome, Human; Genomes; Granuloma - drug therapy; Granuloma - microbiology; Granulomas; Humans; Hypoxia; Infections; Lungs; Microenvironments; Mycobacterium tuberculosis - drug effects; R&D; Research & development; Review; Screening; Tuberculosis
• ISSN: 0009-2665; 1520-6890
• DOI: 10.1021/acs.chemrev.7b00602

Current tuberculosis (TB) drug development efforts are not sufficient to end the global TB epidemic. Recent efforts have focused on the development of whole-cell screening assays because biochemical, target-based inhibitor screens during the last two decades have not delivered new TB drugs. Mycobacterium tuberculosis (Mtb), the causative agent of TB, encounters diverse microenvironments and can be found in a variety of metabolic states in the human host. Due to the complexity and heterogeneity of Mtb infection, no single model can fully recapitulate the in vivo conditions in which Mtb is found in TB patients, and there is no single “standard” screening condition to generate hit compounds for TB drug development. However, current screening assays have become more sophisticated as researchers attempt to mirror the complexity of TB disease in the laboratory. In this review, we describe efforts using surrogates and engineered strains of Mtb to focus screens on specific targets. We explain model culture systems ranging from carbon starvation to hypoxia, and combinations thereof, designed to represent the microenvironment which Mtb encounters in the human body. We outline ongoing efforts to model Mtb infection in the lung granuloma. We assess these different models, their ability to generate hit compounds, and needs for further TB drug development, to provide direction for future TB drug discovery.